Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Armistice Capital lost almost 19% last month, the biggest decline for the hedge fund’s flagship money pool since its launch ...